GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A new study has confirmed that weight loss or bariatric surgery is safe and very effective, and, for a large percentage of ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...

Today, the American Diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

Adults in their 70s with dementia experienced faster weight loss in the decade before diagnosis than their cognitively ...